Shots:
- Profluent has entered into a multi-program strategic research collaboration with Eli Lilly to develop & commercialize custom site-specific recombinases to address diseases with unmet needs
- As per the deal, Profluent will use its AI models to design & optimize site-specific recombinases for multiple genomic targets, while Lilly will gain exclusive rights to selected assets through in vivo research, preclinical & clinical development, & commercialization
- Profluent will receive upfront and R&D funding, with potential development & commercial milestones up to $2.25B plus tiered royalties on net sales, while additional deal terms remain undisclosed
Ref: Businesswire | Image: Profluent & Eli Lilly |Press Release
Related News: Eli Lilly to Acquire Ajax Therapeutics for ~$2.3B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
